VACEK, Lukáš, Michaela KOUŘILOVÁ, Šárka KOBZOVÁ and Lubomír JANDA. Antimicrobial effect of endolysins LYSDERM‐S and LYSDERM‐T1 and endolysin‐ubiquitin combination on methicillin‐resistant Staphylococcus aureus. BIOLOGIA. NEW YORK: SPRINGER, 2023, vol. 78, No 2, p. 601-608. ISSN 0006-3088. Available from: https://dx.doi.org/10.1007/s11756-022-01282-6.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Antimicrobial effect of endolysins LYSDERM‐S and LYSDERM‐T1 and endolysin‐ubiquitin combination on methicillin‐resistant Staphylococcus aureus
Authors VACEK, Lukáš (203 Czech Republic, belonging to the institution), Michaela KOUŘILOVÁ (203 Czech Republic), Šárka KOBZOVÁ (203 Czech Republic) and Lubomír JANDA (203 Czech Republic, guarantor).
Edition BIOLOGIA, NEW YORK, SPRINGER, 2023, 0006-3088.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10606 Microbiology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.500 in 2022
RIV identification code RIV/00216224:14110/23:00134618
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s11756-022-01282-6
UT WoS 000894986000002
Keywords in English Endolysin;Ubiquitin;LYSDERM-S;LYSDERM-T1;Staphylococcus aureus;MRSA
Tags 14110113, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/2/2023 08:14.
Abstract
Bacterial resistance is a major issue in the modern world, and Staphylococcus aureus is one of these well-known multi-resistant species. Staphylococcal infections are one of the leading causes of infection in humans and are becoming more challenging to treat by conventional methods. Endolysins, a novel class of antibacterial agents, are bacteriophage-encoded lytic enzymes capable of degrading peptidoglycan and thus able to kill bacteria. This study aimed to study endolysin LYSDERM-S (a variant of endolysin LysF1 optimized for heterologous expression in E. coli) and newly prepared thermally stabilized endolysin LYSDERM-T1 (with a mutation in the CHAP domain) both with (LYSDERM-US, LYSDERM-UT1) and without fused ubiquitin and determine its role in protein expression and antibacterial activity. The results showed that fused endolysin-ubiquitin proteins did not exceed the antimicrobial effect of endolysins alone, but cleaved endolysin-ubiquitin proteins possessed longer lasting antimicrobial effect than endolysin alone. The biobetter endolysin LYSDERM-T1 with higher thermal stability showed a prolonged antimicrobial effect. Further, we showed that ubiquitin alone possesses antimicrobial properties. Minimal inhibitory and bactericidal concentrations (MIC and MBC) were assessed and confirmed that ubiquitin is able to increase the antimicrobial potential of endolysins. Biobetter endolysins or endolysin-ubiquitin combinations could serve as an alternative to well-established antimicrobial therapy for methicillin-resistant S. aureus infections.
Links
NU22-05-00475, research and development projectName: Léčba infekcí způsobených multirezistentními kmeny bakterií pomocí nových antibakteriálních přípravků založených na katelicidinových antimikrobiálních peptidech
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 17/7/2024 09:33